Abstracts tagged "neopterin"

Abstract Number: 0775 • ACR Convergence 2021
Decreased HDL Levels and Antioxidant Function in Juvenile Dermatomyositis
Amer Khojah¹, Arya Kadakia², Christina Charles-Schoeman³, Jacob Spitznagle⁴, Jennifer Wang³, Ani Shahbazian³, Gabrielle Morgan⁵ and Lauren Pachman⁶, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann and Robert H. Lurie Children’s Hospital, Chicago, IL, ³Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁴Hospital for Special Surgery, New York, NY, ⁵Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Juvenile Dermatomyositis (JDM) is the most common inflammatory myopathy of childhood and is characterized by chronic inflammation targeting muscle and skin. Older patients who…
Abstract Number: 0978 • ACR Convergence 2021
Immunological and Clinical Features of Untreated Juvenile Dermatomyositis Patients with Elevated Neopterin
Amer Khojah¹, Gabrielle Morgan² and Lauren Pachman³, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Neopterin is a metabolic product of guanosine triphosphate, which is produced by macrophages upon stimulation with interferon-gamma from activated T helper cells. Despite the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].